Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel liposome plus cisplatin versus gemcitabine plus cisplatin for stage III-IV NSCLC with regional lymph node metastasis
ChiCTR-TRC-12002105Phase 4Completed
- Sponsor
- Army Medical University
- Start
- Jun 2012
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of liposomal paclitaxel, cisplatin and gemcitabine in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Army Medical University. Primary endpoints: Objective response rate and Change in regional lymph node metastasis and TNM stage. Started Jun 2012; status: completed.
02
Drugs
liposomal paclitaxelcisplatingemcitabine
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR-TRC-12002105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-TRC-12002105.